Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis.

Psychological Medicine
P DazzanC Morgan

Abstract

To determine the baseline individual characteristics that predicted symptom recovery and functional recovery at 10-years following the first episode of psychosis. AESOP-10 is a 10-year follow up of an epidemiological, naturalistic population-based cohort of individuals recruited at the time of their first episode of psychosis in two areas in the UK (South East London and Nottingham). Detailed information on demographic, clinical, and social factors was examined to identify which factors predicted symptom and functional remission and recovery over 10-year follow-up. The study included 557 individuals with a first episode psychosis. The main study outcomes were symptom recovery and functional recovery at 10-year follow-up. At 10 years, 46.2% (n = 140 of 303) of patients achieved symptom recovery and 40.9% (n = 117) achieved functional recovery. The strongest predictor of symptom recovery at 10 years was symptom remission at 12 weeks (adj OR 4.47; CI 2.60-7.67); followed by a diagnosis of depression with psychotic symptoms (adj OR 2.68; CI 1.02-7.05). Symptom remission at 12 weeks was also a strong predictor of functional recovery at 10 years (adj OR 2.75; CI 1.23-6.11), together with being from Nottingham study centre (adj OR 3.2...Continue Reading

References

Jan 1, 1992·Psychological Medicine. Monograph Supplement·A JablenskyA Bertelsen
Nov 1, 1994·Acta Psychiatrica Scandinavica·R TharaW W Eaton
May 1, 1993·Archives of General Psychiatry·J LiebermanM Borenstein
Jul 11, 2000·Acta Psychiatrica Scandinavica. Supplementum·A Leung, P Chue
Jun 5, 2001·The British Journal of Psychiatry : the Journal of Mental Science·G HarrisonD Wiersma
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Jul 5, 2005·Acta Psychiatrica Scandinavica·M LambertB G Schimmelmann
Sep 12, 2006·Schizophrenia Research·Jonathan RabinowitzHeinz Häfner
Jan 2, 2007·The Journal of Clinical Psychiatry·Robin EmsleyH Jadri Turner
Oct 4, 2008·Journal of Psychiatric Practice·Brian J Miller
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Niall CrumlishEadbhard O'Callaghan
Feb 4, 2009·Psychological Medicine·C WhiteS Lewis
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·J van OsR Murray
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Nov 10, 2009·Schizophrenia Research·Ronald BottlenderHans-Jürgen Möller
Mar 13, 2012·The American Journal of Psychiatry·Wenche Ten Velden HegelstadThomas McGlashan
May 24, 2012·Acta Psychiatrica Scandinavica·S VermaS A Chong
Nov 13, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ofer AgidGary Remington
Nov 17, 2015·Psychiatric Services : a Journal of the American Psychiatric Association·Svein FriisThomas H McGlashan
Jan 1, 2016·Schizophrenia Research·Marco ColizziMarta Di Forti
Feb 16, 2017·Schizophrenia Bulletin·Melissa A WeibellSvein Friis
Jun 24, 2017·The British Journal of Psychiatry : the Journal of Mental Science·Craig MorganPaola Dazzan

❮ Previous
Next ❯

Citations

Dec 10, 2019·Psychological Medicine·Svein FriisThomas H McGlashan
Feb 5, 2021·Psychological Medicine·Craig MorganUlrich Reininghaus
Aug 7, 2021·Schizophrenia Bulletin·Petra Verena ViherSebastian Walther
Nov 4, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·Ana CatalanPaolo Fusar-Poli

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.